Research ArticleArticle
The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity
Vivian P. Bykerk, Shahin Jamal, Gilles Boire, Carol A. Hitchon, Boulos Haraoui, Janet E. Pope, J. Carter Thorne, Ye Sun and Edward C. Keystone
The Journal of Rheumatology August 2012, jrheum.120029; DOI: https://doi.org/10.3899/jrheum.120029
Vivian P. Bykerk
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Shahin Jamal
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Gilles Boire
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Carol A. Hitchon
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Boulos Haraoui
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Janet E. Pope
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
J. Carter Thorne
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Ye Sun
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Edward C. Keystone
From Mount Sinai Hospital, University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec; University of Manitoba, Winnipeg, Manitoba; Université de Montréal, CHUM, Hôpital Notre Dame, Montréal, Quebec; St. Joseph’s Health Centre, London, Ontario; and Southlake Regional Health Care, Newmarket, Ontario, Canada. Supported by Amgen Canada Inc., Pfizer Canada Inc., Abbott Laboratories Ltd., Roche, United Chemicals of Belgium (UCB) Canada Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Canada Co., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Dr. Bykerk has been a consultant with Amgen, Pfizer, Abbott, BMS, Roche, and UCB. Dr. Boire has received research grants from Amgen, Novartis, Merck, Procter & Gamble, Servier, Abbott, Janssen, and AstraZeneca; and funding from Canadian Institutes of Health Research and the National Sciences and Engineering Research Council. Dr. Haraoui has received grants from Abbott, Amgen, and Roche. Dr. Pope is supported by Amgen, Abbott, Actelion, BMS, ISIS, Genentech, Novartis, Merck, GSK, MedImmune, Roche, J&J, Pfizer, Teva, and UCB. Dr. Thorne has received consultation fees from Amgen, Pfizer, Abbott, BMS, Roche, and UCB; and grants from Abbott, Amgen, BMS, Merck, Pfizer, Roche, and UCB. Dr. Keystone has consulting agreements/advisory board membership with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Roche, Genentech, Schering-Plough, UCB, and Wyeth; and speaker honorarium agreements with Abbott, Amgen, Bristol-Myers Squibb, Roche, Schering-Plough, and Wyeth. V.P. Bykerk, MD, FRCPC, Mount Sinai Hospital, University of Toronto; Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, USA; S. Jamal, MD, FRCPC, MSc, Clinical Assistant Professor, University of British Columbia; G. Boire, MD, MSc, FRCPC, Division of Rheumatology, Centre Hospitalier Universitaire de Sherbrooke; C.A. Hitchon, MD, FRCPC, MSc, University of Manitoba; B. Haraoui, MD, FRCPC, Associate Professor of Medicine, Université de Montréal, CHUM, Hôpital Notre Dame; J.E. Pope, MD, MPH, FRCPC, St. Joseph’s Health Centre; J.C. Thorne, MD, FRCPC, Southlake Regional Health Care; Y. Sun, PhD, Mount Sinai Hospital; E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, Rebecca MacDonald Centre For Arthritis and Autoimmune Diseases. Address correspondence to Dr. V.P. Bykerk, Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. E mail: vbykerk@gmail.com Accepted for publication June 8, 2012.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity
Vivian P. Bykerk, Shahin Jamal, Gilles Boire, Carol A. Hitchon, Boulos Haraoui, Janet E. Pope, J. Carter Thorne, Ye Sun, Edward C. Keystone
The Journal of Rheumatology Aug 2012, jrheum.120029; DOI: 10.3899/jrheum.120029
The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity
Vivian P. Bykerk, Shahin Jamal, Gilles Boire, Carol A. Hitchon, Boulos Haraoui, Janet E. Pope, J. Carter Thorne, Ye Sun, Edward C. Keystone
The Journal of Rheumatology Aug 2012, jrheum.120029; DOI: 10.3899/jrheum.120029